We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
+32.15%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$901M
AUM Growth
-$183M
Cap. Flow
-$318M
Cap. Flow %
-35.32%
Top 10 Hldgs %
45.07%
Holding
107
New
16
Increased
16
Reduced
34
Closed
34

Top Buys

Rank Stock Value
1
HCA icon
HCA Healthcare
HCA
+$25.1M
2
PEN icon
Penumbra
PEN
+$17.6M
3
IDYA icon
IDEAYA Biosciences
IDYA
+$16.9M
4
GSK icon
GSK
GSK
+$12M
5
NUVL
Nuvalent
NUVL
+$10.4M

Top Sells

Rank Stock Value
1
TGTX icon
TG Therapeutics
TGTX
+$26M
2
ACLX
Arcellx
ACLX
+$21.9M
3
PODD icon
Insulet
PODD
+$20.4M
4
EOLS icon
Evolus
EOLS
+$19M
5
CRL icon
Charles River Laboratories
CRL
+$18.8M

Sector Composition

Rank Sector Weight
1 Healthcare 99.95%
2 Consumer Staples 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SNDX icon
26
Syndax Pharmaceuticals
SNDX
$1.72B
$11.1M 1.23%
514,000
+394,500
+330% +$6.06M
TGTX icon
27
TG Therapeutics
TGTX
$7.5B
$11.1M 1.23%
650,000
-2,234,382
-77% -$26M
CCCC icon
28
C4 Therapeutics
CCCC
$396M
$10.4M 1.15%
1,835,996
-856,024
-32% -$1.95M
BCAB icon
29
BioAtla
BCAB
$5.56M
$10M 1.11%
81,304
-5,820
-7% -$505K
TMDX icon
30
Transmedics
TMDX
$2.52B
$9.72M 1.08%
+123,112
New +$7.43M
HARP
31
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$9.33M 1.04%
+820,638
New +$6.45M
ACLX
32
DELISTED
Arcellx
ACLX
$8.82M 0.98%
159,000
-484,777
-75% -$21.9M
CMPS
33
Compass Pathways
CMPS
$1.72B
$8.44M 0.94%
964,550
– –
TNGX icon
34
Tango Therapeutics
TNGX
$4.71B
$8.39M 0.93%
847,145
-1,081,874
-56% -$9.39M
MRUS
35
DELISTED
Merus
MRUS
$8.32M 0.92%
302,577
-81,913
-21% -$1.91M
VKTX icon
36
Viking Therapeutics
VKTX
$3.87B
$8.12M 0.9%
436,200
+314,000
+257% +$4.11M
JSPR icon
37
Jasper Therapeutics
JSPR
$21.6M
$7.79M 0.86%
987,098
+157,000
+19% +$1.05M
THTX
38
DELISTED
Theratechnologies
THTX
$7.78M 0.86%
4,801,376
+2,470,000
+106% +$3.72M
RVMD icon
39
Revolution Medicines
RVMD
$41.4B
$7.23M 0.8%
+252,000
New +$6.06M
SIBN icon
40
SI-BONE Inc
SIBN
$798M
$7.17M 0.8%
341,818
-300,471
-47% -$5.56M
SILK
41
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$6.59M 0.73%
+537,000
New +$5.04M
PHVS icon
42
Pharvaris
PHVS
$2.31B
$6.1M 0.68%
217,396
-126,579
-37% -$2.56M
INSM icon
43
Insmed
INSM
$21.6B
$5.18M 0.57%
167,100
-50,900
-23% -$1.32M
KRYS icon
44
Krystal Biotech
KRYS
$9.38B
$4.96M 0.55%
40,000
-77,892
-66% -$8.64M
CVS icon
45
CVS Health
CVS
$125B
$4.7M 0.52%
59,500
-133,054
-69% -$9.47M
IOVA icon
46
Iovance Biotherapeutics
IOVA
$1.97B
$4.51M 0.5%
555,000
-684,777
-55% -$3.58M
NVCR icon
47
NovoCure
NVCR
$1.87B
$4.49M 0.5%
301,000
-43,100
-13% -$577K
NSPR icon
48
InspireMD
NSPR
$33.4M
$3.87M 0.43%
1,378,128
– –
VRDN icon
49
Viridian Therapeutics
VRDN
$2.3B
$3.01M 0.33%
+138,000
New +$2.18M
DNLI icon
50
Denali Therapeutics
DNLI
$3.83B
$2.79M 0.31%
+130,000
New +$2.57M
1
2
3 4 5

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
BL
Balentine LLC Atlanta, Georgia $2.48B AUM 17.44% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return
Q
QVR San Francisco, California $2.49B AUM 48.58% 1-Year Est. Return
SIM
Stratos Investment Management Beachwood, Ohio $2.49B AUM 17.24% 1-Year Est. Return

Soleus Capital Management's Q4 2023 Portfolio in Review

As of Q4 2023, Soleus Capital Management held 107 positions worth $901M, down 17% from $1.08B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Soleus Capital Management withdrew a net $318M in Q4 2023, closing 34 positions and reducing 34 holdings. Its most notable exit was Insulet, an estimated $20.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 90% a quarter earlier, followed by Consumer Staples.

Against the trend, Soleus Capital Management opened a new position in HCA Healthcare worth $27.5M.

  • Soleus Capital Management's largest Q4 2023 buy was HCA Healthcare: 101,500 shares worth $27.5M.
  • Soleus Capital Management added most to GSK in Q4 2023, an estimated $12M increase.
  • Soleus Capital Management's biggest Q4 2023 reduction was TG Therapeutics, cutting an estimated $26M.
  • Soleus Capital Management fully exited Insulet in Q4 2023, selling an estimated $20.4M.
  • Soleus Capital Management's ten largest holdings make up 45% of its $901M portfolio in Q4 2023.
  • Soleus Capital Management opened 16 new positions and closed 34 in Q4 2023.
  • Soleus Capital Management's portfolio value fell 17% quarter-over-quarter to $901M.

Based on Soleus Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.